Una sperimentazione in aperto (open label) di fase I/IIa che ripropone la carbamazepina (CBZ) per il trattamento di displasia scheletrica nei bambini

Title

Code

MCDS-Therapy

Type

Sperimentale

Start Year

2022

Status

Terminato

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio farmacologico prot. MCDS-Therapy

Tuesday 19 July 2022, 14:51

PG0003923_2022_ prot. MCDS-Therapy.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

Una sperimentazione in aperto (open label) di fase I/IIa che ripropone la carbamazepina (CBZ) per il trattamento di displasia scheletrica nei bambini

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in